The Day's Play Edition 202: US healthcare deal, oil production growth and Queensland gas results | AYA, BAS, OMA
Artrya (ASX:AYA)
HonorHealth Agreement Expands US Commercial Footprint
Artrya has secured a 5-year commercial agreement with Arizona-based HonorHealth, with a minimum contracted value of US$0.5M for its Salix Coronary Anatomy platform. HonorHealth becomes Artrya’s 5th US commercial customer and first secured outside its foundation customers and SAPPHIRE study participants. Deployment will span 9 acute-care hospitals serving a population of approximately 5 million, with additional fee-per-scan revenue possible from Salix Coronary Plaque and, subject to FDA clearance, Salix Coronary Flow.
Read full ASX Announcement here.
Bass Oil (ASX:BAS)
October Production Rises 28% as Revenue Reaches A$1.83M
Bass Oil recorded October production of 13,146 barrels, up 28%, with average daily output of 424 bopd, up 24%. Revenue increased 8.3% to A$1.83M. Indonesian production contributed 10,726 barrels net to Bass, up 37%, following Bunian 6 coming online. Planning has commenced for up to 2 follow-up wells in 2027, with a reserve update underway. Vanessa gas field recommissioning remains on budget and on schedule for year-end start-up.
Read full ASX Announcement here.
Omega Oil & Gas (ASX:OMA)
Queensland’s Deepest Well Records Highest Gas Shows to Date
Omega Oil & Gas has completed Canyon North-1 at 4,700m measured depth, making it Queensland’s deepest well. Drilling recorded the company's highest gas shows to date, with gas influx from the unstimulated Muggleton Formation safely flared at surface. High gas shows were also recorded in the Canyon Sandstone and Lower Kianga formations. No flow rates have been measured. Wireline logging is next, followed by Canyon North-2, with horizontal appraisal and flow testing targeted for 1H 2027, subject to well results and joint venture approval.
Read full ASX Announcement here.
Cavalier Resources (ASX:CVR)
Crawford Completes Final Pre-Mining Fieldwork
Cavalier Resources has completed its final planned pre-production fieldwork at the Crawford Gold Project, including initial water bore drilling and geotechnical investigations for the proposed haul road and heap leach pad. All primary mining approvals are in place, while preferred contractor SSH Mining has completed its site inspection and the Mining Services Agreement is progressing towards execution. Project financing remains the key priority before mining can commence.
Read full ASX Announcement here.
Breakthrough Minerals (ASX:BTM)
Errolls Divestment Unlocks $1.2M in Shareholder Value
Breakthrough Minerals has entered into a binding term sheet to sell 100% of its Errolls Gold Project subsidiary to Xenora Minerals (ASX:XRA) for $1.2M in consideration shares, comprising 6 million XRA shares at a deemed issue price of $0.20 each. Subject to transaction completion and required approvals, BTM intends to distribute the shares to eligible shareholders through an in-specie distribution. The shares will be subject to 12-month voluntary escrow. The divestment sharpens BTM’s focus on its North Queensland Copper-Gold Project.
Read full ASX Announcement here.
Advance Metals (ASX:AVM)
$6M Gold Spin-Out Targets 2027 ASX Listing
Advance Metals and Sky Metals have signed a non-binding term sheet to combine 5 Australian gold projects into a proposed ASX-listed NewCo, covering more than 2,000km² across Victoria and NSW. Advance would receive a 37.5% stake and Sky 18.75%, representing combined deemed consideration of $9M in NewCo shares. NewCo is targeting a $6M IPO and ASX listing in 1H 2027. The proposal remains subject to due diligence, formal agreements, shareholder and regulatory approvals, and IPO completion.
Read full ASX Announcement here.
Neurizon Therapeutics (ASX:NUZ)
First HEALEY ALS Participant Enters Active Treatment Extension
The first participant in Neurizon’s Phase 2/3 HEALEY ALS Platform Trial has completed the 36-week randomised phase and entered the Active Treatment Extension (ATE). The optional 36-week extension will generate additional long-term safety, tolerability, functional and biomarker data, with all participants receiving NUZ-001 regardless of their original treatment allocation. Regimen I is fully enrolled with 250 participants across 78 US sites. Topline randomised-phase results remain targeted for late Q2 2027.
Read full ASX Announcement here.
Osmond Resources (ASX:OSM)
Three Orión Holes Intersect Prospective Quartzite
Osmond Resources has intersected prospective Pochico Formation quartzites in all 3 completed Phase 2 drill holes at its Orión Project in Spain, with downhole thicknesses of 2.60m, 2.80m and 3.20m. The holes target an area classified as Inferred within the existing 60Mt Mineral Resource. Samples have been submitted for assay, with results pending. A third drill rig has arrived on site, while the 4th and 5th holes are underway to support the planned resource upgrade.